16^th World Hematology Congress

Statement of the Problem: Blood typing using serology can provide an inaccurate answer if a patient is recently transfused, taking oncology therapeutics like Darzalex, or has weak or partial antigens. Antisera are not always available for rare antigens. Chronically transfused patients can avoid alloimmunization by receiving antigen-negative blood units, but building a complete patient or donor antigen profile using serology is labor-intensive and can take days. Blood genotyping using traditional methods such as SSP and SSO overcome the limitations of serotyping, but require long, labor-intensive workflows and limited resolution. Blood genotyping using Sanger or NGS sequencing technology have high resolution, but are even more time and labor consuming, expensive and require interpretation by subject matter experts.

 

Solution: Thermo Fisher Scientific’s Link SÄ“q real-time PCR technology accelerates turn-around times reducing laboratory costs and provides medium to high resolution results that can be interpreted by clinicians and interrogated

by genotyping experts. LinkSÄ“q utilizes allele specific PCR reactions to identify important variants and its SureTyper™ software analyzes reaction results to automatically determine the genotype and predict a phenotype. LinkSÄ“q was developed over 10 years ago for genotyping the complex Human Leukocyte Antigen (HLA) system and can be performed on the same equipment as real-time PCR based HLA typing assays, which are widely used for deceased donor typing.

 

Conclusion & Significance: LinkSÄ“q blood genotyping solutions overcome the major challenges of molecular typing by providing a robust, automated approach that increases laboratory productivity and reduces turn-around time.

With less than 10 minutes of hands on set-up, no further operator intervention with reagents and SureTyper software by fully automating all analysis, LinkSÄ“q delivers genotyping and predicted phenotyping results in approximately 90 minutes.